Expert Interview
Reviewing IDEAYA Biosciences' recent Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma patients
Ticker(s): IDYAInstitution: Cleveland Clinic
- Director of the Department of Ophthalmology Oncology at the Cleveland clinic
- Treats 100 new patients a year with uveal melanom
- Published over 320 scientific articles and has edited several textbooks while being the editor of the Ocular Oncology and Pathology journal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
